The twiist™ AID system powered by Tidepool receives 510(k) clearance

Every day at Tidepool, we move closer to increasing patient choice in automated insulin delivery (AID) systems, actively leading efforts to enhance device integration and functionality. Today, we are excited to announce a new milestone in our diabetes innovation journey - a new partnership with Sequel Med Tech, LLC. 

Sequel’s new twiist Automated Insulin Delivery (AID) system powered by Tidepool’s Loop technology to automatically adjust insulin delivery based on CGM readings and predicted glucose levels, received FDA 510(k) clearance.

We are thrilled about the opportunity to provide even more choices for people with diabetes and their care teams by making the Tidepool Loop algorithm compatible with as many insulin pumps and CGMs as possible. At Tidepool, we strongly believe in a world where you can choose the diabetes technology that works best for you. Device partnerships like the one with Sequel Med Tech, LLC, are essential in paving the way forward for diabetes technology with more individualized choices.  

This new AID solution for the diabetes community would not be possible without the DIY community. Our commitment is, first and foremost, to people living with diabetes, and we are determined to provide solutions designed to help you put diabetes in the background.

We are excited about celebrating even more milestones with each new innovation built upon our FDA-cleared Tidepool Loop algorithm. In doing so, we hope to inspire more device manufacturers to join us in this journey toward patient choice. 

Want to stay up to date on the newest developments and partnerships? Fill out our Tidepool Loop Interest Form.

Disclaimer: The twiist™ AID system powered by Tidepool is not yet available for use.